You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
双成药业(002693.SZ)半年度净亏损1456.05万元
格隆汇 08-15 16:44

格隆汇8月15日丨双成药业(002693.SZ)发布2019年半年度报告,实现营业收入1.78亿元,同比增长0.60%;归属于上市公司股东的净亏损1456.05万元,同比收窄22.58%;基本每股亏损0.04元。

报告期内,公司研发投入1873.51元,占营业收入的10.54%。经过多年的艰苦努力,已建成具有国际研发注册和专利挑战能力、集多肽原料药与制剂仿制药开发为一体、研发技术队伍梯队较为完整的研发体系。在高水平引路人的带领、研发团队不懈努力和生产质量等各部门的紧密配合下,报告期内,在研项目稳步推进,20191月获得国家药品监督管理局批准签发的“注射用比伐芦定”《药品注册批件》,并已提交了一致性评价申请;公司对注射用比伐芦定在美国专利挑战成功,并向FDA递交了正式批准申请;注射用胸腺法新一致性评价申请已于2018年上半年递交;生长抑素原料药工艺优化已完成,注射用生长抑素的一致性评价研发已在进行中;注射用泮托拉唑钠已基本完成一致性评价研究。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account